Try a new search

Format these results:

Searched for:

person:auerbr01

Total Results:

86


Histologic evaluation of nail clippings for diagnosing onychomycosis

Suarez SM; Silvers DN; Scher RK; Pearlstein HH; Auerbach R
Nail clippings from patients suspected of having onychomycosis were processed for histologic evaluation in the same manner as routine skin with the addition of a chitin-softening solution prior to processing. The sections were stained by the periodic acid-Schiff method and examined for fungal hyphae. The results were compared with the results of fungal cultures from the same nail. Our findings indicate that routine histopathologic analysis of the nail plate alone is a useful complementary method to fungal culture for diagnosing onychomycosis
PMID: 1834026
ISSN: 0003-987x
CID: 38333

Topical chemotherapy in treatment of skin cancer

Chapter by: Auerbach R
in: Cancer of the skin by Friedman RJ; Rigel DS; Kopf AW; Harris MN; Baker D [Eds]
Philadelphia : WB Saunders, 1991
pp. 466-469
ISBN: 072162328x
CID: 3106

Giant keratoacanthoma: an atypical presentation [Case Report]

Edelman BA; Jacobs JB; Rotterdam H; Auerbach R
PMID: 2122381
ISSN: 0194-5998
CID: 38361

Excision of congenital nevi: immediate, complete, and in the office [Letter]

Auerbach R
PMID: 2313848
ISSN: 0098-7484
CID: 38349

The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment

Newman M; Auerbach R; Feiner H; Holzman RS; Shupack J; Migdal P; Culubret M; Camuto P; Tobias H
Liver biopsy specimens from 168 patients who underwent a total of 364 biopsies were examined. Of 83 patients receiving biopsies before methotrexate treatment, 14 had one or more risk factors predictive of liver abnormality but they had normal pretreatment biopsy specimens. Among 17 patients with abnormal biopsy specimens before methotrexate treatment, only 1 had an identifiable risk factor and 5 had abnormal results of liver function tests. The probability of a normal biopsy specimen after methotrexate treatment dropped below 50% at a cumulative methotrexate dose of 3115 mg for the 31 patients with biopsy specimens from before and after methotrexate treatment and 5776 mg for those who had biopsies only after methotrexate treatment; this difference was statistically significant and is thought to be related to the fact that the patients who had biopsies before and after methotrexate treatment had received most of their medication by the parenteral rather than the oral route. A significant association existed between biopsy grade after methotrexate treatment and obesity. Other risk factors were not correlated with biopsy grade. Blood chemistry tests were not predictive of histopathologic findings. Eight of 11 patients with fibrosis or cirrhosis showed meaningful improvement in liver histologic findings after methotrexate treatment had been withdrawn for 6 months or more; none had progression of abnormalities
PMID: 2774597
ISSN: 0003-987x
CID: 10501

Acquired reactive perforating collagenosis [Case Report]

Cohen RW; Auerbach R
PMID: 2915063
ISSN: 0190-9622
CID: 10724

Methotrexate in psoriasis: revised guidelines

Roenigk HH Jr; Auerbach R; Maibach HI; Weinstein GD
PMID: 3042816
ISSN: 0190-9622
CID: 38363

THE IMPORTANCE OF SERIAL LIVER BIOPSIES IN THE METHOTREXATE TREATMENT OF PSORIASIS [Meeting Abstract]

Newman, M; Auerbach, R; Finer, H; Holzman, R; Migdal, P; Culbret, M; Camuto, P; Tobias, H
ISI:A1987K265000293
ISSN: 0270-9139
CID: 31120

REVERSIBILITY OF METHOTREXATE-ASSOCIATED HEPATIC-FIBROSIS [Meeting Abstract]

Camuto, P; Newman, M; Culubret, M; Migdal, P; Auerbach, R; Tobias, H; Feiner, H
ISI:A1987F618700068
ISSN: 0023-6837
CID: 31287

Malignant melanoma in situ in two patients treated with psoralens and ultraviolet A [Case Report]

Marx JL; Auerbach R; Possick P; Myrow R; Gladstein AH; Kopf AW
Two patients are reported who were treated with 8-methoxypsoralen and ultraviolet A (PUVA) for psoriasis and developed cutaneous lesions of malignant melanoma in situ (atypical melanocytic hyperplasia). One patient received 324.5 joules/cm2 of UVA. Seven months after discontinuing therapy, he developed a superficial spreading melanoma in situ in association with an intradermal nevus on the left posterior thoracic area. The second patient received 2,802 joules/cm of UVA. While on PUVA therapy she developed an in situ lentigo melanoma on her lower lip. To our knowledge only one other psoriatic patient and one patient with vitiligo have developed malignant melanomas after PUVA therapy, so that an increased incidence of malignant melanomas after PUVA therapy, so that an increased incidence of malignant melanoma following PUVA is not documented
PMID: 6643789
ISSN: 0190-9622
CID: 38364